Farmacogenetica in de psychiatrie; de huidige status quo

Translated title of the contribution: Farmacogenetica in de psychiatrie; de huidige status quo

R. van Westrhenen, T. K. Birkenhäger

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Medication side effects and limited efficacy are substantial problems in general and also in psychopharmaceuticals. Previous studies have shown that pharmacogenetic individual characteristics can be relevant. AIM: To arrive at a responsible use of pharmacogenetics, exploiting its potential but also avoiding overdiagnosis. METHOD: To provide an overview of the current status quo in the field of pharmacogenetics in psychiatry. RESULTS: The Dutch Association for Psychiatrists (NVvP) authorized a guideline ‘Pharmacogenetics in Psychiatry’ that is summarized. Also the current international guidelines and clinical implementation of pharmacogenetics are discussed. CONCLUSION: For the time being, pharmacogenetics seems to be indicated only when patients have already experienced problems with psychopharmaca use, such as side effects and/or inefficacy. If genotyping is requested then generally CYP2C19 and CYP2D6 can be useful, as dosage recommendations are available in case of genetic variants.

Translated title of the contributionFarmacogenetica in de psychiatrie; de huidige status quo
Original languageDutch
Pages (from-to)312-316
Number of pages5
JournalTijdschrift voor Psychiatrie
Volume64
Issue number5
Publication statusPublished - 10 May 2022

Fingerprint

Dive into the research topics of 'Farmacogenetica in de psychiatrie; de huidige status quo'. Together they form a unique fingerprint.

Cite this